Akero Therapeutics (AKRO) Competitors $28.25 +0.60 (+2.17%) (As of 04:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AKRO vs. ALBO, ENTA, CBAY, ITCI, LNTH, RVMD, ELAN, VKTX, NUVL, and BPMCShould you be buying Akero Therapeutics stock or one of its competitors? The main competitors of Akero Therapeutics include Albireo Pharma (ALBO), Enanta Pharmaceuticals (ENTA), CymaBay Therapeutics (CBAY), Intra-Cellular Therapies (ITCI), Lantheus (LNTH), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Viking Therapeutics (VKTX), Nuvalent (NUVL), and Blueprint Medicines (BPMC). These companies are all part of the "medical" sector. Akero Therapeutics vs. Albireo Pharma Enanta Pharmaceuticals CymaBay Therapeutics Intra-Cellular Therapies Lantheus Revolution Medicines Elanco Animal Health Viking Therapeutics Nuvalent Blueprint Medicines Albireo Pharma (NASDAQ:ALBO) and Akero Therapeutics (NASDAQ:AKRO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability. Is ALBO or AKRO more profitable? Akero Therapeutics has a net margin of 0.00% compared to Albireo Pharma's net margin of -228.51%. Akero Therapeutics' return on equity of -29.50% beat Albireo Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Albireo Pharma-228.51% -97.13% -46.89% Akero Therapeutics N/A -29.50%-27.23% Does the MarketBeat Community prefer ALBO or AKRO? Albireo Pharma received 193 more outperform votes than Akero Therapeutics when rated by MarketBeat users. However, 62.87% of users gave Akero Therapeutics an outperform vote while only 54.98% of users gave Albireo Pharma an outperform vote. CompanyUnderperformOutperformAlbireo PharmaOutperform Votes29854.98% Underperform Votes24445.02% Akero TherapeuticsOutperform Votes10562.87% Underperform Votes6237.13% Does the media prefer ALBO or AKRO? In the previous week, Akero Therapeutics had 9 more articles in the media than Albireo Pharma. MarketBeat recorded 9 mentions for Akero Therapeutics and 0 mentions for Albireo Pharma. Akero Therapeutics' average media sentiment score of 0.58 beat Albireo Pharma's score of 0.20 indicating that Akero Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Albireo Pharma Neutral Akero Therapeutics Positive Do institutionals and insiders hold more shares of ALBO or AKRO? 94.3% of Albireo Pharma shares are held by institutional investors. 6.9% of Albireo Pharma shares are held by company insiders. Comparatively, 7.9% of Akero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, ALBO or AKRO? Albireo Pharma has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Albireo Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlbireo Pharma$40.58M22.52-$34.03M-$6.72-6.57Akero TherapeuticsN/AN/A-$151.76M-$3.20-8.83 Do analysts recommend ALBO or AKRO? Akero Therapeutics has a consensus target price of $41.13, indicating a potential upside of 45.58%. Given Akero Therapeutics' higher possible upside, analysts clearly believe Akero Therapeutics is more favorable than Albireo Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Albireo Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AAkero Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Which has more risk & volatility, ALBO or AKRO? Albireo Pharma has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.26, indicating that its stock price is 126% less volatile than the S&P 500. SummaryAkero Therapeutics beats Albireo Pharma on 10 of the 16 factors compared between the two stocks. Ad InvestorPlace“A very dark day is coming to America”Wall Street Legend on Economy: "If you knew what I know, you'd be terrified too." Something huge is headed to America's shores – and it scares the hell out of Wall St. legend Louis Navellier. When it makes landfall, its impact will be more violent and more severe than any financial crisis we've ever seen… "No matter how prepared you think you are, you aren't prepared enough," he warns.Click here to see his official warning. Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKRO vs. The Competition Export to ExcelMetricAkero TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.95B$7.52B$5.52B$8.46BDividend YieldN/A5.48%4.49%4.09%P/E Ratio-8.8319.27138.6518.53Price / SalesN/A250.321,651.2873.27Price / CashN/A40.2238.7533.65Price / Book2.945.844.884.56Net Income-$151.76M$151.22M$115.45M$224.60M7 Day Performance0.04%6.98%2.94%2.57%1 Month Performance7.41%22.98%15.49%12.41%1 Year Performance-38.64%30.92%29.39%22.70% Akero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKROAkero Therapeutics3.3797 of 5 stars$28.25+2.2%$41.13+45.6%-41.7%$1.95BN/A-8.8330Insider SellingALBOAlbireo PharmaN/A$44.15-0.2%N/A+0.0%$913.91M$40.58M-6.57130Analyst ForecastENTAEnanta Pharmaceuticals3.9746 of 5 stars$10.05-4.0%$19.00+89.1%+3.8%$212.85M$71.96M-1.61160CBAYCymaBay Therapeutics0.9446 of 5 stars$32.48flat$32.50+0.1%+126.3%$3.73B$31.07M-33.48101Analyst ForecastITCIIntra-Cellular Therapies4.8328 of 5 stars$73.30+0.1%$96.58+31.8%+40.3%$7.74B$563.44M-63.19560Analyst ForecastPositive NewsLNTHLantheus4.7935 of 5 stars$107.36+2.8%$126.00+17.4%+42.7%$7.44B$1.44B16.39700Positive NewsRVMDRevolution Medicines3.9692 of 5 stars$44.17+0.7%$54.00+22.3%+88.1%$7.38B$11.58M-11.78250Insider SellingELANElanco Animal Health3.7735 of 5 stars$14.32+4.3%$17.43+21.7%+38.1%$7.08B$4.49B-5.409,300Gap UpVKTXViking Therapeutics4.712 of 5 stars$61.63-1.1%$108.60+76.2%+495.3%$6.80BN/A-66.2720NUVLNuvalent2.1514 of 5 stars$99.10-1.9%$111.00+12.0%+144.0%$6.40BN/A-41.1240Analyst ForecastInsider SellingBPMCBlueprint Medicines3.4578 of 5 stars$92.55+3.9%$120.00+29.7%+81.5%$5.80B$362.80M-19.24640Positive News Related Companies and Tools Related Companies: Albireo Pharma Alternatives Enanta Pharmaceuticals Alternatives CymaBay Therapeutics Alternatives Intra-Cellular Therapies Alternatives Lantheus Alternatives Revolution Medicines Alternatives Elanco Animal Health Alternatives Viking Therapeutics Alternatives Nuvalent Alternatives Blueprint Medicines Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AKRO) was last updated on 10/4/2024 by MarketBeat.com Staff From Our PartnersHow a $200,000 Mistake Unlocked a $118 Billion Gold TreasureThe window of opportunity on this gold stock is closing fast. Once word gets out, it may be too late.Monument Traders Alliance | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | Sponsored“A very dark day is coming to America”Wall Street Legend on Economy: "If you knew what I know, you'd be terrified too." Something huge is headed ...InvestorPlace | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredNext opportunity for crypto millionsAll the Pieces Falling into Place for Crypto… Unlock the Potential of the 2024 Crypto Bull Run!Crypto 101 Media | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredNo matter the outcome of the election, it could be a death sentence for your wealth...In today's financial landscape, many investors are feeling disillusioned and disappointed with traditional inv...Allegiance Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
